Hermetica Superfood Encyclopedia
The Short Answer
Uncaria guianensis contains pentacyclic oxindole alkaloids (POAs), catechin (91.10 mg/100g), epigallocatechin (9.51 mg/g), and chlorogenic acid, which inhibit phospholipase A2 (10–46%), suppress TNFα with an IC50 of 9.5 ng/mL in LPS-stimulated macrophages, and demonstrate superior DPPH free-radical scavenging compared to U. tomentosa. Preclinical data show aqueous bark extracts inhibit thrombolysis by up to 53% and provide erythrocyte membrane protection of 14–60%, establishing the strongest evidence base for anti-inflammatory and antioxidant activity, though no human randomized controlled trials have yet been published.
CategoryHerb
GroupAmazonian
Evidence LevelPreliminary
Primary KeywordUncaria guianensis benefits
Uncaria guianensis — botanical close-up
Health Benefits
**Anti-Inflammatory Activity**
Aqueous extracts inhibit phospholipase A2 by 10–46% and reduce TNFα production in LPS-stimulated RAW 264.7 macrophages with an IC50 of 9.5 ng/mL, outperforming U. tomentosa (IC50 14.1 ng/mL, p<0.01), attributable to synergistic action of POA alkaloids and polyphenols on pro-inflammatory signaling cascades.
**Immune Modulation**
Pentacyclic oxindole alkaloids (POAs) present in the bark are associated with immune cell stimulation, particularly enhancement of phagocytic activity and modulation of cytokine release, providing a mechanistic basis for traditional use in immune support alongside polyphenolic co-constituents.
**Antioxidant Defense**: U
guianensis demonstrates superior DPPH radical scavenging capacity compared to U. tomentosa despite similar or lower total alkaloid content, driven by higher concentrations of catechin (91.10 mg/100g), epigallocatechin (9.51 mg/g), and epicatechin that donate hydrogen atoms to neutralize reactive oxygen species.
**Erythrocyte Membrane Protection**: In venom-model assays, U
guianensis extracts inhibit hemolysis by 14–60%, indicating direct stabilization of red blood cell membranes; this effect is linked to polyphenol intercalation within phospholipid bilayers and inhibition of membrane-disrupting phospholipases.
**Thrombolytic Regulation**
High-dose aqueous extracts reduce experimentally induced thrombolysis by up to 53%, suggesting a potential role in modulating coagulation-related pathways; the mechanism is partially attributed to inhibition of proteolytic enzymes and phospholipase A2 activity rather than direct anticoagulant alkaloid action.
**Proteolytic Enzyme Inhibition**
Bark extracts inhibit proteolytic activity by 10–40% in in vitro assays using venom models, a finding that may translate to attenuation of tissue-degrading enzymatic activity relevant to inflammatory joint and connective tissue conditions.
**Free Radical Scavenging and Cellular Redox Support**
The combined phenolic matrix—catechins, chlorogenic acid, and proanthocyanidins—provides a broad-spectrum antioxidant profile that protects cellular components from oxidative damage, with ORAC-equivalent values in related Uncaria bark extracts reaching up to 18.8 mmol TE/g.
Origin & History
Natural habitat
Uncaria guianensis is a woody climbing vine native to the Amazon basin and tropical rainforests of South America, including Peru, Brazil, Colombia, and Guyana, typically thriving in humid lowland and montane forest environments at elevations below 800 meters. It belongs to the Rubiaceae family and is closely related to Uncaria tomentosa, the more commercially prevalent cat's claw species, though U. guianensis is distinguished by its slightly different alkaloid and polyphenolic profile. The vine has been harvested by indigenous Amazonian communities for centuries, with bark and root preparations constituting the primary forms used in traditional medicine.
“Uncaria guianensis has been used for generations by indigenous Amazonian peoples, most notably the Asháninka of the Peruvian Amazon, who prepared bark decoctions for the treatment of inflammatory conditions, rheumatic pain, infections, and wound healing—applications collectively referred to under the broader 'uña de gato' (cat's claw) tradition shared with U. tomentosa. The vine's common name derives from the distinctive hook-shaped thorns lining the stem, which resemble cat's claws and guided indigenous identification in dense forest environments. Although U. tomentosa gained wider international commercial recognition during the late 20th century, particularly after its introduction to European herbal medicine markets in the 1970s–1980s, U. guianensis has remained a parallel ethnobotanical resource of considerable local importance throughout the Amazon basin. Historical accounts document bark harvesting from mature wild vines using strip-harvesting techniques intended to preserve plant viability, reflecting a traditional conservation ethic embedded in indigenous horticultural practice.”Traditional Medicine
Scientific Research
The current evidence base for Uncaria guianensis consists entirely of in vitro cell-culture studies and ex vivo biochemical assays, with no published human randomized controlled trials as of the available literature; this places the ingredient at a preclinical evidence tier. Key experimental data derive from comparative studies measuring PLA2 inhibition, hemolysis, proteolytic activity, and TNFα release, where U. guianensis aqueous bark extracts consistently outperformed U. tomentosa on TNFα suppression (IC50 9.5 vs. 14.1 ng/mL, p<0.01) and DPPH scavenging. Phytochemical quantification studies have characterized the polyphenolic fingerprint—including catechin at 91.10 ± 0.51 mg/100g and epigallocatechin at 9.51 ± 0.01 mg/g—providing reproducible compositional benchmarks, though dose-response relationships in humans remain unestablished. The body of evidence, while mechanistically coherent, is limited in translational confidence due to the absence of pharmacokinetic data, bioavailability studies, and clinical outcome trials in human populations.
Preparation & Dosage
Traditional preparation
**Traditional Aqueous Decoction (Bark)**
250–500 mL water for 15–30 minutes; the preparation used historically by Asháninka communities and consistent with the aqueous extraction methods employed in published phytochemical studies
1–4 grams of dried bark simmered in .
**Standardized Bark Extract (Capsule/Tablet)**
250–500 mg standardized extract taken 1–2 times daily
No formally validated standardization has been established for U. guianensis specifically; by analogy with U. tomentosa commercial products, extracts are often standardized to 15% polyphenolics or 3–4% total alkaloids, with typical doses of .
**Dry Bark Powder (Bulk Supplement)**
500 mg–1,500 mg per day in divided doses represents a commonly referenced range for Uncaria species generally; no pharmacokinetic dose-finding studies have been published for U
guianensis to confirm optimal intake.
**Tincture/Hydroalcoholic Extract**
2–4 mL (approximately 40–80 drops) up to three times daily; this format may enhance extraction of both alkaloids and polyphenolics relative to pure aqueous preparations
1:5 tinctures in 40–60% ethanol at .
**Timing Note**
No specific timing data are available; consistent daily administration rather than acute dosing is recommended based on the proposed immunomodulatory and anti-inflammatory mechanisms requiring sustained pathway modulation.
Nutritional Profile
Uncaria guianensis bark is not a significant source of macronutrients or conventional micronutrients; its nutritional relevance is defined almost entirely by its phytochemical matrix. Quantified polyphenolics include catechin at 91.10 ± 0.51 mg/100g dry weight, epigallocatechin at 9.51 ± 0.01 mg/g extract, and epicatechin alongside chlorogenic acid in concentrations that surpass those reported for U. tomentosa in comparative analyses. Alkaloids—primarily pentacyclic oxindole alkaloids (POAs) such as isopteropodine, mitraphylline, and speciophylline, alongside tetracyclic oxindole alkaloids (TOAs)—are present in concentrations analogous to U. tomentosa averages (~26.9 mg/g POA, ~2.75 mg/g TOA), though precise U. guianensis-specific alkaloid quantification remains incompletely characterized in the published literature. Proanthocyanidins, triterpenes (including ursolic and oleanolic acid analogs), and saponins round out the bioactive profile; polyphenol bioavailability is expected to be moderate and influenced by gut microbiota catechin biotransformation, food matrix interactions, and first-pass hepatic metabolism, though no dedicated pharmacokinetic studies exist for this species.
How It Works
Mechanism of Action
The primary anti-inflammatory mechanism of Uncaria guianensis centers on inhibition of phospholipase A2 (PLA2), a key enzyme that liberates arachidonic acid from membrane phospholipids to initiate the prostaglandin and leukotriene synthesis cascade; aqueous bark extracts suppress PLA2 activity by 10–46% in vitro, thereby reducing upstream substrate availability for COX and LOX pathways. Pentacyclic oxindole alkaloids (POAs), including isopteropodine and mitraphylline analogs, modulate macrophage activation by suppressing TNFα transcription and release, as evidenced by an IC50 of 9.5 ng/mL in LPS-challenged RAW 264.7 cells, likely through partial inhibition of NF-κB nuclear translocation. Polyphenolic constituents—particularly catechin, epigallocatechin, and chlorogenic acid—contribute through direct radical quenching, metal chelation, and inhibition of NADPH oxidase-mediated reactive oxygen species generation, which synergistically reduces oxidative amplification of inflammatory signaling. Proanthocyanidins and flavanols additionally stabilize erythrocyte and endothelial membranes by integrating into phospholipid bilayers and competitively inhibiting membrane-bound phospholipases, explaining the observed 14–60% hemolysis inhibition in ex vivo models.
Clinical Evidence
No human clinical trials have been conducted specifically on Uncaria guianensis; all quantified outcomes originate from in vitro or ex vivo experimental models using aqueous or ethanolic bark extracts. The most compelling preclinical findings are the TNFα suppression IC50 of 9.5 ng/mL in LPS-stimulated macrophages and 10–53% inhibition of venom-induced enzymatic and thrombolytic damage across dose gradients. While the closely related Uncaria tomentosa has been evaluated in small clinical studies for osteoarthritis and DNA repair (predominantly open-label or pilot trials with sample sizes of 30–45 participants), these data are not directly transferable to U. guianensis given documented differences in alkaloid and flavonoid composition. Overall confidence in clinical efficacy for U. guianensis is low due to an absence of RCT-level evidence, and conclusions must be considered hypothesis-generating rather than confirmatory.
Safety & Interactions
The safety profile of Uncaria guianensis in humans is not formally characterized, as no clinical trials have evaluated adverse events, maximum tolerated doses, or drug interactions in human subjects; extrapolation from U. tomentosa data suggests low acute toxicity at typical supplemental doses, and in vitro assays show selectivity for abnormal cell lines without toxicity to normal cells. Tetracyclic oxindole alkaloids (TOAs), present at lower concentrations than POAs, are theorized to antagonize some POA-mediated immune effects, and alkaloid chemotype variability between plant populations may produce inconsistent physiological responses. Potential drug interactions of concern—informed by mechanistic and U. tomentosa class-effect data—include additive anticoagulant risk with warfarin, heparin, or antiplatelet agents given the observed thrombolytic inhibition; immunosuppressant interactions are theoretically possible given macrophage-modulating activity. Uncaria species are generally contraindicated in pregnancy due to reported uterotonic potential in animal models, during lactation, in pediatric populations under 3 years of age, and in individuals receiving organ transplants or immunosuppressive therapy; individuals with autoimmune conditions should consult a clinician before use.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Uncaria guianensis (Aubl.) Gmel.Peruvian cat's clawUña de gato (Amazonian variety)Garabato amarilloCat's claw vine
Frequently Asked Questions
What is the difference between Uncaria guianensis and Uncaria tomentosa?
Uncaria guianensis and U. tomentosa are both Amazonian cat's claw species but differ in their phytochemical composition: U. guianensis contains higher concentrations of catechin (91.10 mg/100g) and epigallocatechin (9.51 mg/g) and demonstrates superior DPPH antioxidant scavenging, while U. tomentosa shows higher caffeic and p-coumaric acid content and has a more extensively studied alkaloid profile (~29.6 mg/g total alkaloids). In TNFα suppression assays, U. guianensis outperforms U. tomentosa with an IC50 of 9.5 ng/mL versus 14.1 ng/mL (p<0.01), suggesting potentially greater anti-inflammatory potency per unit concentration despite fewer published clinical studies.
What are the main active compounds in Uncaria guianensis?
The primary bioactive constituents of Uncaria guianensis include pentacyclic oxindole alkaloids (POAs) such as isopteropodine and mitraphylline analogs, which modulate macrophage TNFα production, alongside a rich polyphenolic fraction comprising catechin (91.10 ± 0.51 mg/100g), epigallocatechin (9.51 ± 0.01 mg/g), epicatechin, and chlorogenic acid that drive antioxidant and membrane-protective effects. Proanthocyanidins, triterpenes, and saponins are also present and contribute to the overall anti-inflammatory and cytoprotective activity observed in preclinical models.
Is there clinical evidence supporting Uncaria guianensis for immune support?
Currently, no human randomized controlled trials have been published specifically for Uncaria guianensis; all immune-supportive evidence derives from in vitro cell assays and ex vivo biochemical models, including macrophage TNFα suppression (IC50 9.5 ng/mL) and phospholipase A2 inhibition (10–46%). While these preclinical findings are mechanistically coherent with traditional use claims, they cannot be directly extrapolated to confirmed clinical efficacy, and U. guianensis should be considered a preliminary-evidence botanical requiring human trial validation.
What is the recommended dosage for Uncaria guianensis supplements?
No standardized dosage has been established through human pharmacokinetic or clinical studies for Uncaria guianensis specifically; by extrapolation from U. tomentosa commercial guidelines and traditional decoction practices, typical supplemental use involves 250–500 mg of standardized bark extract (targeting 3–4% total alkaloids or 15% polyphenolics) taken once or twice daily, or 1–4 grams of dried bark as a traditional aqueous decoction. Given the absence of clinical dose-finding data, individuals should start at lower doses and consult a healthcare provider, particularly if taking anticoagulants or immunomodulatory medications.
Is Uncaria guianensis safe to use, and are there any drug interactions?
Uncaria guianensis lacks formal human safety data, but preclinical models indicate low acute toxicity and selectivity for abnormal versus normal cell types; however, its thrombolytic-inhibiting activity and macrophage-modulating alkaloids create theoretical interactions with anticoagulants (warfarin, heparin), antiplatelet agents, and immunosuppressive drugs. The herb is generally contraindicated during pregnancy due to potential uterotonic effects observed in animal studies, and should be avoided by individuals with autoimmune diseases, those on organ transplant medications, and children under 3 years of age.
How does Uncaria guianensis compare to Uncaria tomentosa for reducing inflammation?
Uncaria guianensis demonstrates superior anti-inflammatory potency compared to U. tomentosa, with aqueous extracts reducing TNFα production in stimulated macrophages at an IC50 of 9.5 ng/mL versus 14.1 ng/mL for U. tomentosa (p<0.01). This enhanced efficacy is attributed to the synergistic action of pentacyclic oxindole alkaloids and polyphenols working together on pro-inflammatory signaling pathways. U. guianensis also inhibits phospholipase A2 by 10–46%, making it potentially more effective for individuals seeking anti-inflammatory support.
What extract form of Uncaria guianensis offers the best anti-inflammatory benefits?
Aqueous extracts of Uncaria guianensis have demonstrated the strongest anti-inflammatory activity in clinical research, showing marked inhibition of phospholipase A2 and TNFα production in immune cells. The aqueous extraction method effectively preserves both pentacyclic oxindole alkaloids and polyphenolic compounds, which work synergistically to modulate inflammatory cascades. When selecting a supplement, look for aqueous or water-based extract formulations rather than dry powder alone to maximize the anti-inflammatory potential demonstrated in scientific studies.
Who benefits most from Uncaria guianensis supplementation?
Individuals seeking immune support and those concerned with inflammatory responses may benefit most from Uncaria guianensis, particularly given its superior anti-inflammatory activity compared to related species. People managing occasional joint discomfort or those with inflammatory conditions may find value in its pentacyclic oxindole alkaloid content and polyphenolic activity. Those interested in traditional Amazonian herbal practices or seeking botanical alternatives to conventional anti-inflammatory approaches are also ideal candidates for supplementation.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w cats-claw-peruvian-uncaria-guianensis curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
